-
CHS national committees – What do they do? What are they?
You have heard us say it, you have read about it: we are deeply grateful for the work and time and dedication of our volunteers … But have you...
Research projects funded in 2024
It is safe to say that research provides better quality of life and will lead, one day, inevitably to cures. This is why the Canadian Hemophilia Society (CHS) is...
Opportunity to take part in a hemophilia B gene therapy trial
Hamilton, January 22, 2024 – McMaster University, in collaboration with CSL Behring, has announced a new gene therapy trial for etranacogene dezaparvovec (Hemgenix) in hemophilia B. Hemgenix received its...
Gene Therapy Education Program – A CHS comprehensive information program
The hemophilia community has been waiting for gene therapy for years; many hoped it would be a cure. Quantitative and qualitative results from late stages of clinical trials for...
-
-
-
Update on coagulation products – current and in the pipeline
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
-
-
Our continuing efforts to raise awareness about women and bleeding disorders
-
Health Canada approves Hemgenix gene therapy for hemophilia B
-
New shared decision-making tool (SDM) by the World Federation of Hemophilia
-
-
